# Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

> **NCT01285765** · PHASE3 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 650 (actual)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** RCHOP21

## Key facts

- **NCT ID:** NCT01285765
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2020-05-23
- **Final completion:** 2020-05-23
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285765, "Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01285765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*